Guardant Health, INC

Guardant Health reported a 44% year-over-year revenue increase to $335.0 million for the second quarter of 2026, driven by strong performance in Oncology and Screening, leading to an upward revision of full-year revenue guidance.

Guardant Health's annual meeting saw directors elected and auditor ratified, but advisory executive compensation vote failed.

Guardant Health reported a 48% year-over-year revenue increase to $301.7 million for Q1 2026, driven by strong oncology and screening performance, leading to an upward revision of full-year revenue guidance.

Guardant Health, Inc. announced the resignation of Chief Medical Officer Craig Eagle, M.D., effective May 8, 2026.

Guardant Health announced robust fourth quarter and full year 2025 financial results, driven by significant growth in oncology and screening revenue, alongside a positive 2026 outlook.

Guardant Health announced preliminary unaudited Q4 and full year 2025 results, showing significant revenue and test volume growth driven by oncology and screening.

Guardant Health reported a 44% increase in Q2 2026 revenue to $335 million, driven by strong performance in oncology and screening tests, though net loss also widened.

Guardant Health reports strong revenue growth of 48% year-over-year for Q1 2026, driven by significant expansion in screening and oncology test volumes.

Guardant Health reported a 39% surge in third-quarter revenue, driven by strong adoption of its Shield colorectal cancer screening test and oncology portfolio, while significantly narrowing its net loss.

Guardant Health, a precision oncology company, reported significant revenue increases for Q2 and H1 2025, driven by the commercial launch of its Shield colorectal cancer screening test and growth in oncology test volumes, while also reducing its net loss despite increased operating expenses and navigating complex legal proceedings.

Guardant Health's Q1 2025 revenue increased by 21% compared to Q1 2024, driven by growth in oncology and biopharma segments, alongside the launch of the Shield screening test.

Guardant Health's Q3 2024 results show a significant increase in revenue, primarily driven by a 35% growth in precision oncology testing.

Guardant Health, a precision oncology company, reported a 33% increase in total revenue to $982.0 million for fiscal year 2025, driven by growth across its oncology, biopharma, and newly commercialized screening segments, despite continued net losses.

Guardant Health reports revenue growth in its 2024 10-K filing, driven by increased testing volume and reimbursement, but continues to operate at a net loss.

Guardant Health's 2023 10-K filing highlights its commitment to precision oncology, expansion of product offerings, and strategic collaborations amidst ongoing financial losses and a complex regulatory landscape.

Roberto Mignone, a Director of Guardant Health, Inc., reported multiple transactions in common stock on July 21, 2026.

Medina Manuel Hidalgo, a Director of Guardant Health, Inc., reported multiple transactions in common stock on July 17, 2026.

Musa Tariq, a Director of Guardant Health, Inc., sold 116 shares of common stock on July 15, 2026 for $163.29 per share.

Guardant Health's Chief Legal Officer, John G. Saia, reported transactions involving the acquisition of common stock and restricted stock units.

Terilyn J. Monroe, Chief People Officer at Guardant Health, Inc., reported transactions involving restricted stock units and common stock.

Guardant Health, Inc. executive Kumud Kalia reported transactions involving the acquisition of common stock and restricted stock units.

Guardant Health invites stockholders to its 2026 Annual Meeting on June 17, 2026, reporting 33% revenue growth to $982 million in 2025.

Guardant Health is holding a stockholder meeting to vote on the election of Class I directors, the ratification of Deloitte & Touche LLP as their independent auditor, and an advisory vote on executive compensation.

Guardant Health achieved significant milestones in 2024, including FDA approval of Shield and a 31% revenue increase, setting a positive trajectory for 2025.

Guardant Health, Inc. has scheduled its annual stockholder meeting for June 12, 2024, and is seeking votes on the election of directors, ratification of auditors, and executive compensation.

Guardant Health's proxy statement details the agenda for the 2024 Annual Meeting of Stockholders and recaps a year of solid growth and strategic advancements in 2023.

T. Rowe Price Associates, Inc. has reported beneficial ownership of 5.4% of Guardant Health Inc.'s common stock as of March 31, 2026.

Vanguard Capital Management has reported beneficial ownership of 5.02% of Guardant Health Inc.'s common stock as of March 31, 2026.

The Vanguard Group has filed an amended Schedule 13G, reporting 0% beneficial ownership in Guardant Health Inc. following an internal realignment.

Deep Track Capital, LP and its affiliates have filed an amended Schedule 13G, disclosing a 4.41% beneficial ownership stake in Guardant Health, Inc. as of March 31, 2025.

BlackRock, Inc. has filed an updated Schedule 13G, reaffirming its substantial passive ownership of 7.5% of Guardant Health, Inc.'s common stock as of March 31, 2025.

Cadian Capital Management, LP, along with its general partner and managing member Eric Bannasch, has disclosed a beneficial ownership of 4.2% in Guardant Health, Inc. as of December 31, 2024.